No UK Marketing Authorisation Identified No current UK marketing authorisation for a medicinal product containing emideltide free peptide or emideltide acetate was identified in the official product sources reviewed for this article
BPC 157 therapy consistently holds g-ng dose range applied alone without carrier addition and has no sequence homology with known gut peptides [1,2,3,4,5,6,7,8,9,10,11,15,27,28,29,30,33]
According to the company, the serum has been its strongest launch to date in terms of units sold, setting records for both first-day sales and first-week sales, over-delivering on its four-week unit forecast by 10%, and selling out on Sephora.com
BPC157 is emerging as a powerful therapy for Crohns disease